Copyright
©2014 Baishideng Publishing Group Inc.
World J Hepatol. Aug 27, 2014; 6(8): 613-620
Published online Aug 27, 2014. doi: 10.4254/wjh.v6.i8.613
Published online Aug 27, 2014. doi: 10.4254/wjh.v6.i8.613
Table 1 Clinical and demographic characteristics of non-alcoholic fatty liver disease patients and controls
Variable | NAFLD (n = 20) | Control (n = 20) | P |
Age (yr) | 42.75 ± 8.17 | 44.50 ± 9.31 | 0.761 |
Sex (male/female) | 9 (45.0)/11(55.0) | 9 (45.0)/11 (55.0) | 0.761 |
BMI (kg/m2) | 31.86 ± 4.76 | 27.26 ± 3.07 | 0.006 |
Waist circumference (cm) | 103.25 ± 13.65 | 90.75 ± 11.02 | 0.014 |
Systolic blood pressure (mmHg) | 120.25 ± 8.66 | 120.25 ± 7.69 | 0.999 |
Diastolic blood pressure (mmHg) | 76.50 ± 6.09 | 77.50 ± 8.96 | 0.761 |
Fasting glucose (mg/dL) | 97.85 ± 13.88 | 86.80 ± 11.92 | 0.034 |
Triglycerides (mg/dL) | 151.10 ± 65.06 | 167.70 ± 51.46 | 0.645 |
HDL-C (mg/dL) | 43.00 (36.50-48.50) | 45.00 (38.45-49.95) | 0.761 |
LDL-C (mg/dL) | 125.50 (100.00-139.00) | 108.00 (89.25-121.25) | 0.511 |
Insulin (mIU/mL) | 14.81 (11.88-22.75) | 11.76 (8.61-15.70) | 0.229 |
HOMA-IR | 4.05 (2.71-5.51) | 2.21 (1.77-3.12) | 0.034 |
Total biluribin (mg/dL) | 0.65 (0.50-0.80) | 0.60 (0.55-0.80) | 0.761 |
Direct biluribin (mg/dL) | 0.20 (0.12-0.25) | 0.20 (0.10-0.20) | 0.761 |
AST (IU/L) | 45.00 (34.50-59.00) | 21.00 (18.00-27.00) | < 0.001 |
ALT (IU/L) | 68.50 (52.50-85.50) | 18.50 (14.00-29.00) | < 0.001 |
AP (IU/L) | 76.00 (55.50-96.00) | 69.00 (57.00-78.50) | 0.761 |
GGT (IU/L) | 48.00 (33.00-73.00) | 20.00 (14.50-33.00) | < 0.001 |
Creatinine (mg/dL) | 0.87 ± 0.15 | 0.80 ± 0.18 | 0.401 |
WBC (μL) | 6709.50 ± 1709.47 | 6618.00 ± 1425.37 | 0.892 |
Trombocyte (103/μL) | 252.10 ± 64.85 | 275.90 ± 69.82 | 0.511 |
Hct | 43.37 ± 3.53 | 44.25 ± 4.19 | 0.761 |
Table 2 Log2 (Fold change) ratios of differentially expressed miRNAs which were statistically significant by t test (P < 0.05) and further confirmed by SAM test (q < 5%)
miRNAs | log2 (Fold change) | q value (%) | |
Mean | SEM | ||
Over-expressed | |||
- | - | - | - |
Under-expressed | |||
miR-197 | -1.61 | 0.54 | 0 |
miR-146b | -1.52 | 0.55 | 0 |
miR-181d | -2.49 | 0.50 | 0 |
miR-99a | -1.92 | 0.53 | 0 |
Table 3 Point-biserial correlation coefficients between NAS-scale parameters and miRNAs in non-alcoholic fatty liver disease patients
miR-197 | miR-146b | miR-10b | miR-181d | miR-34a | miR-122 | miR-99a | miR-29a | |
Steatosis | 0.229 | 0.191 | 0.179 | 0.179 | 0.245 | 0.067 | 0.311 | 0.256 |
Inflammation | -0.4571 | -0.396 | -0.4921 | -0.402 | -0.302 | -0.23 | -0.431 | -0.315 |
Ballooning | 0.154 | 0.114 | 0.175 | 0.254 | 0.165 | -0.037 | -0.029 | 0.096 |
Fibrosis | -0.112 | -0.171 | -0.213 | -0.098 | 0.033 | -0.137 | -0.197 | -0.103 |
NAS | 0.051 | 0.015 | 0.035 | 0.069 | 0.124 | -0.027 | 0.074 | 0.041 |
Table 4 Correlation analysis between laboratory parameters and miRNAs in non-alcoholic fatty liver disease patients
miR-197 | miR-146b | miR-10b | miR-181d | miR-34a | miR-122 | miR-99a | miR-29a | |
AST | -0.257 | -0.331 | -0.225 | -0.252 | -0.084 | -0.225 | -0.138 | -0.322 |
ALT | -0.131 | -0.147 | -0.080 | -0.215 | 0.122 | 0.103 | 0.077 | -0.143 |
GGT | -0.327 | -0.225 | -0.303 | -0.4641 | -0.29 | -0.231 | -0.4791 | -0.221 |
Triglyceride | 0.008 | -0.039 | 0.009 | -0.035 | -0.075 | 0.087 | -0.239 | -0.058 |
HDL-C | 0.027 | 0.051 | -0.031 | 0.042 | 0.052 | 0.111 | 0.16 | 0.034 |
LDL-C | 0.078 | 0.042 | 0.067 | 0.015 | 0.139 | 0.102 | 0.213 | 0.155 |
HOMA-IR | -0.055 | 0.117 | 0.011 | -0.015 | 0.195 | 0.205 | 0.221 | 0.177 |
Table 5 Statistical diagnostic measures for miR-197, miR-146b, miR-181d and miR-99a in identifying non-alcoholic fatty liver disease
miRNA | Cut-off value | SEN (95%CI) | SPE (95%CI) | PPV (95%CI) | NPV (95%CI) |
miR-197 | ≤ -1.0144 | 60.0 (36.1-80.9) | 95.0 (75.1-99.9) | 92.3 (64.0-99.8) | 70.4 (49.8-86.2) |
miR-146b | ≤ -0.7689 | 55.0 (31.6-76.9) | 100.0 (83.0-100.0) | 100.0 (71.3-100.0) | 69.0 (49.2-84.7) |
miR-181d | ≤ -0.2861 | 70.0 (45.7-88.0) | 85.0 (62.1-96.6) | 82.4 (56.6-96.0) | 73.9 (51.6-89.7) |
miR-99a | ≤ -0.1562 | 65.0 (40.8-84.5) | 95.0 (75.1-99.2) | 92.9 (66.1-98.8) | 73.1 (52.2-88.4) |
- Citation: Celikbilek M, Baskol M, Taheri S, Deniz K, Dogan S, Zararsiz G, Gursoy S, Guven K, Ozbakır O, Dundar M, Yucesoy M. Circulating microRNAs in patients with non-alcoholic fatty liver disease. World J Hepatol 2014; 6(8): 613-620
- URL: https://www.wjgnet.com/1948-5182/full/v6/i8/613.htm
- DOI: https://dx.doi.org/10.4254/wjh.v6.i8.613